Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899390 | 1.00 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3899383 | 1.00 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1383607 | 0.92 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1383609 | 0.92 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1383608 | 0.92 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL14093676 | 0.92 | OPRL1 (0.50) | OPRL1OPRM1OPRK1 | |
| SCHEMBL1037786 | 0.90 | OPRL1 (0.49) | OPRL1OPRM1OPRK1 | |
| SCHEMBL1037784 | 0.90 | OPRL1 (0.49) | OPRL1OPRM1OPRK1 | |
| SCHEMBL1037782 | 0.90 | OPRL1 (0.49) | OPRL1OPRM1OPRK1 | |
| SCHEMBL1381751 | 0.90 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778956-B2 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| EP-1601674-B1 | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-08 | — | — | EP | disclosed |
| US-7582649-B2 | Oral administration of a dosage of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and a carrier; opiod receptor-like-1 G-protein coupled receptor inhibitors; psychological disorders; nervous system disorders; antidiabetic agents | JANSSEN PHARMACEUTICA, NV (BE) | 2009-09-01 | — | — | US | disclosed |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | BATTISTA KATHLEEN | 2009-05-14 | — | — | US | disclosed |
| US-7081463-B2 | Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20060030577-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | BATTISTA KATHLEEN | 2006-02-09 | — | — | US | disclosed |
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | OPRL1, GPR4, ADRA1D | OPRL1 1/4885OPRM1 21/4885OPRK1 5/4885 |
| US-20060030577-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, ADRA1D, OPRD1 | OPRL1 1/4885OPRM1 14/4885OPRK1 4/4885 |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | OPRL1, ADRA1D, OPRD1 | OPRL1 1/4885OPRM1 14/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.